Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Human parainfluenza virus type 1 hemagglutinin-neuraminidase protein (HPIV-1 HN protein)
- Target
- HPIV-1 HN protein
- Molecular classification
- Viral surface glycoprotein, Enzyme (neuraminidase activity), Other (virus attachment and fusion mediator)
01
Overview
The human parainfluenza virus type 1 hemagglutinin-neuraminidase protein is a multifunctional surface glycoprotein located on the viral envelope. It binds to host cell sialic acid residues, mediating virus attachment and entry, and possesses neuraminidase activity that cleaves sialic acids, facilitating viral spread. The HN protein is the main antigenic determinant for protective antibodies and is the principal target for neutralizing agents, making it an important focus for vaccine and therapeutic development. Antigenic diversity and immune selection pressures drive strain evolution and can impact the efficacy of antibody-based therapies and vaccines.
- Other names
- Parainfluenza hemagglutinin-neuraminidaseHPIV-1 HNHuman parainfluenza virus type 1 HNHPIV-1 hemagglutinin-neuraminidaseHPIV1 HN protein
02
Mechanism of action
Neutralizing antibodies: Block HN-mediated attachment and fusion; neutralize infectivity by preventing cell entry. Fusion inhibitors: Prevent fusion protein activation and viral entry. (No approved neuraminidase inhibitors for HPIV-1; the HN neuraminidase activity is a theoretical target.)
03
Biological functions
Attachment to host cell (recognizes receptor on respiratory epithelial cells)Facilitation of viral entryEnzymatic cleavage of sialic acids (neuraminidase activity)Immune evasion and antigenic variation
04
Disease associations
Infection (primarily acute respiratory tract infection in humans, including croup, bronchitis, pneumonia, and other lower respiratory illnesses)
05
Safety considerations
No approved therapeutics, so safety profile is unknownGeneral viral target challenges include antigenic variation, immune selection leading to escape mutantsPossible cross-reactivity with other parainfluenza virus antigens
06
Interacting drugs
No FDA-approved drugs currently target HPIV-1 directly
1 more in the full profile.
07
Biomarkers
Circulating antibodies against HPIV-1 HN protein are used diagnostically to confirm infection and immunityDetection of HPIV-1 RNA or antigen in clinical specimens (PCR, ELISA)
Beyond the preview
Go deeper on Human parainfluenza virus type 1 hemagglutinin-neuraminidase protein (HPIV-1 HN protein).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Human parainfluenza virus type 1 hemagglutinin-neuraminidase protein (HPIV-1 HN protein).